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Contribution of endogenous glucocorticoids and their intra-
vascular metabolism by 11β-HSDs to post-angioplasty
neointimal proliferation in mice
Javaid Iqbal, Linsay J Macdonald, Lucinda Low, Jonathan R. Seckl, Christopher W Yau,
Brian R Walker, and Patrick WF Hadoke*
University/BHF Centre for Cardiovascular Science, University of Edinburgh, U.K.
Abstract
Exogenous glucocorticoids inhibit neointimal proliferation in animals. We aime to test the
hypothesis that endogenous glucocorticoids influence neointimal proliferation; this may be
mediated by effects on systemic risk factors or locally in vessels, and modulated either by adrenal
secretion or by enzymes expressed in vessels which mediate local inactivation (11β-HSD2 in
endothelium) or regeneration (11β-HSD1 in smooth muscle) of glucocorticoids. Femoral artery
wire-angioplasty was conducted in C57Bl/6J, Apo-E−/−, 11β-HSD1−/−, Apo-E, 11β-HSD1−/−
(double knockout) and 11β-HSD2−/− mice following glucocorticoid administration,
adrenalectomy, glucocorticoid or mineralocorticoid receptor antagonism, or selective 11β-HSD1
inhibition. In C57Bl/6J mice, neointimal proliferation was reduced by systemic or local
glucocorticoid administration, unaffected by adrenalectomy, reduced by the mineralocorticoid
receptor antagonist eplerenone, and increased by the glucocorticoid receptor antagonist RU38486.
11β-HSD2 deletion had no effect on neointimal proliferation, with or without eplerenone. 11β-
HSD1 inhibition or deletion had no effect in chow-fed C57Bl/6J mice, but reduced neointimal
proliferation in Apo-E−/− mice on Western diet. Reductions in neointimal size were accompanied
by reduced macrophage and increased collagen content. We conclude that pharmacological
administration of glucocorticoid receptor agonists or of mineralocorticoid receptor antagonists
may be useful in reducing neointimal proliferation. Endogenous corticosteroids induce beneficial
glucocorticoid receptor activation and adverse mineralocorticoid receptor activation. However,
manipulation of glucocorticoid metabolism has beneficial effects only in mice with exaggerated
systemic risk factors, suggesting effects mediated primarily in liver and adipose rather than intra-
vascular glucocorticoid signalling. Reducing glucocorticoid action with 11β-HSD1 inhibitors that
are being developed for type 2 diabetes appears not to risk enhanced neointimal proliferation.
Keywords
Glucocorticoids; mineralocorticoids; Angioplasty; Neointimal proliferation; 11β-hydroxysteroid
dehydrogenases (11β-HSDs)
*Corresponding Author: University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen’s Medical
Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, U.K. Tel: +44 (0) 131 242 6770. Fax: +44 (0) 131 242
6779 patrick.hadoke@ed.ac.uk.
Disclosure statement: JI, LJM, LL, CWY and PWFH have no potential conflicts of interest/disclosures relevant to this article. BRW
and JRS are inventors on relevant patents owned by the University of Edinburgh and have consulted for several companies developing
selective 11βHSD1 inhibitors.
Europe PMC Funders Group
Author Manuscript
Endocrinology. Author manuscript; available in PMC 2014 April 07.
Published in final edited form as:
Endocrinology. 2012 December ; 153(12): 5896–5905. doi:10.1210/en.2012-1481.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
INTRODUCTION
Neointimal proliferation is a key factor determining the success or failure (re-stenosis) of
angioplasty in occlusive vascular disease. It also provides a paradigm through which to gain
insights into vascular responses to injury that are relevant to other vascular lesions, notably
atheroma. Glucocorticoids have anti-proliferative and anti-inflammatory properties that have
been exploited pharmacologically to reduce post-angioplasty neointimal proliferation in rats,
rabbits and dogs, albeit that human trials of glucocorticoid administration, either
systemically or by stent elution, have had mixed results (reviewed in (1)). However, the
influence, if any, of endogenous glucocorticoid signalling on neointimal proliferation
remains uncertain. This is important since variations in circulating and/or intracellular
glucocorticoid concentrations have been associated with cardiovascular disease risk (2), and
new therapies targeted at reducing intracellular glucocorticoid action are emerging (3).
Endogenous glucocorticoids (corticosterone in rodents and cortisol in humans) activate
intracellular glucocorticoid (GR) and mineralocorticoid (MR) receptors. In many cell types,
GR activation is amplified by local regeneration of glucocorticoids by 11β-hydroxysteroid
dehydrogenase type-1 (11β-HSD1) (4), and MR activation is prevented by local inactivation
of glucocorticoids by another isozyme, 11β-HSD2 (5). GR, MR and both isozymes of 11β-
HSD are expressed in the blood vessel wall, with 11β-HSD1 predominantly localised to
vascular smooth muscle cells and 11β-HSD2 present in endothelial cells (1, 6, 7). It has been
shown that MR antagonism with spironolactone or eplerenone attenuates post-angioplasty
neointimal proliferation in rabbits (8) and pigs (9, 10). Moreover, there is evidence from
mice that 11β-HSD2 modifies vascular function by maintaining endothelium-dependent
vasodilatation (11), while 11β-HSD1 modifies vascular remodelling by providing a tonic
restraint on angiogenesis (12). However, there is a paucity of data concerning interactions
between the 11β-HSDs and corticosteroid receptors in modulating neointimal proliferation.
11β-HSD1 is of particular relevance to vascular lesion development. Selective 11β-HSD1
inhibitors are in development for treating type 2 diabetes (3), by reducing intracellular
glucocorticoid concentrations in metabolic tissues such as adipose and liver. However, 11β-
HSD1 is also expressed in macrophages, where loss of regeneration of glucocorticoids
during 11β-HSD1 inhibition may be pro-inflammatory (13, 14). Macrophages have an
established pro-inflammatory role in vascular lesion development both in atherogenesis (15)
and neointimal proliferation, where they are implicated as targets for the therapeutic effects
of glucocorticoids (16). There is, therefore, a concern that 11β-HSD1 inhibitors could
adversely affect cardiovascular outcomes. Reassuringly, in atherogenesis models in mice,
11β-HSD1 inhibition is either protective or neutral for progression of atheroma (17, 18), but
any influence on neointimal proliferation has not been explored.
We hypothesised that variations in endogenous glucocorticoids influence neointimal
proliferation. We investigated neointimal proliferation following intra-vascular femoral
artery injury in mice. Using mice with targeted deletion of 11β-HSD1 or 11β-HSD2 in
combination with pharmacological receptor antagonists or an 11-HSD1 inhibitor, we tested
whether: (1) activation of GR by endogenous glucocorticoids attenuates neointimal
proliferation; (2) activation of MR by endogenous glucocorticoids promotes neointimal
proliferation; (3) 11β-HSD1 activity amplifies GR activation and hence reduces neointimal
proliferation; and (4) 11β-HSD2 activity attenuates MR activation and hence reduces
neointimal proliferation.
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MATERIALS AND METHODS
Animals
All animal work was carried out under UK Home Office licence in accordance with the
Animals (Scientific Procedures) Act, 1986 and conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of Health.
Male C57Bl/6J mice (Harlan Laboratories, UK), Apo-E−/− mice (Charles River
Laboratories, Kent, UK), 11β-HSD2−/− mice homozygous for a disrupted hsd11b2 allele
(bred in house (19)) and 11β-HSD1−/− mice homozygous for a disrupted hsd11b1 allele
(bred in house (20)) and mice with double 11β-HSD1−/−/ ApoE−/− (generated in-house by
crossing the two lines) were studied aged 12 weeks. All lines were congenic on a C57Bl/6J
background. Animals were maintained under standard conditions of light (lights on
8am-8pm) and temperature (21-22°C). Systolic blood pressure (BP), where indicated, was
measured weekly in conscious, warmed, restrained mice using tail-cuff photo-
plethysmography.
Materials
Unless stated otherwise, chemicals were purchased from Sigma-Aldrich, UK. Compound
544 (3-(1-adamantyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-α]azepine), a potent and
selective inhibitor of 11β-HSD1 (17), was obtained from Enamine Ltd., Ukraine. Standard
chow (RM1) was obtained from Special Diet Services (Witham, UK) and Western diet
(OpenSource™ D12079B) was obtained from Research Diets Inc. (Brunswick, USA).
Femoral artery wire injury
Neointimal proliferation was induced by insertion of an angioplasty guide-wire into the
femoral artery, as described previously (21). Briefly, mice were anaesthetised with
isoflurane inhalation (5% for induction and 2% for maintenance, adequacy assessed by loss
of pedal withdrawal reflex), and a small skin incision made in the proximal thigh. A fixed
core straight 0.015″ diameter guide-wire (COOK Inc., Bloomington, USA) was introduced
into the popliteal artery via an arteriotomy, advanced 5-10 mm into the common femoral
artery towards the iliac artery, left in place for 1 minute and then removed. The popliteal
artery was then ligated proximal to the arteriotomy site and blood flow restored in the
common femoral artery. This induced endothelial denudation and stretching of the artery
wall, followed by reperfusion of blood over the injured area. For local drug administration, a
pocket was created next to the injured artery and a silastic pellet inserted. The wound was
closed using silk sutures and the animals were allowed to recover.
Adrenalectomy
Adrenalectomy or sham surgery was conducted under isoflurane anaesthesia 1 week before
femoral artery injury. Adrenalectomised mice were maintained with 0.9% NaCl in their
drinking water. Plasma corticosterone or cortisol levels were measured on trunk blood
samples obtained at sacrifice. Cortisol was measured using a radioimmunoassay kit (ICN
Biomedicals Inc, U.S.A.), as per manufacturer’s instructions. Corticosterone was measured
using an in-house radioimmunoassay (22), using a rabbit anti-corticosterone primary
antibody (diluted 1:100 in borate buffer; kindly provided by C. Kenyon),) and an anti-rabbit
secondary antibody linked to scintillation proximity assay (SPA) beads (diluted according to
manufacturer’s instructions; GE Healthcare, U.K.). Intra-assay and inter-assay coefficients
of variation for this assay were 4.6–6.2% and 6.4–8.2%, respectively.
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Drug administration
Dexamethasone was administered daily (in the morning) as a subcutaneous injection of a 0.1
mg/ml solution in 4% ethanol:96% normal saline. Silastic pellets (10 mg) were prepared, as
previously described (12, 23), containing silastic medical grade elastomer base with 10%
curing agent (Dow Corning, USA) ± 2 mg cortisol or 3.3 mg RU38486. Eplerenone (Pfizer
Inc., New York, USA) was mixed with chow (1.7 mg/g) to achieve a dose of ~200 mg/kg/
day (24). The 11β-HSD1 inhibitor compound 544 was mixed with chow or western diet, as
appropriate, to achieve a daily dose of ~30 mg/kg/day (17). Both eplerenone and compound
544 were administered for 1 week prior to intravascular injury and for 3 weeks thereafter
until the animals were sacrificed.
Evaluation of lesions
Animals were killed by decapitation or perfusion fixation, as appropriate, 21 days after intra-
vascular injury. Trunk blood was collected and organs dissected and weighed. Femoral
arteries were cleaned of connective tissue, and excised from the bifurcation of the iliac
artery to the branch with the popliteal artery. Femoral arteries were immediately placed in
10% neutral buffered formalin, fixed for up to 24 hours and then stored in 70% ethanol if
necessary.
All histological analyses were conducted by an observer who was blind to the group from
which the sections were obtained. The arteries were dehydrated in a graded alcohol series,
embedded in paraffin and cut into transverse sections. Sections were stained with United
States Trichrome (UST). Images of stained sections were digitised using a Photometrics
CoolSnap camera (Roper Scientific, Tucson, USA) coupled to a light microscope via a
microcolour liquid crystal turnable RGB filter (Cambridge Research and Instrumentation
Inc., Woburn, USA). Microcomputer Imaging Device software (MCID; Imaging Research
Inc., St. Catherines, Canada) was used for image analysis of sections every 60 μm along the
length of the artery. The area (μm2) inside the lumen and the areas inside the internal and
external elastic laminae (IEL and EEL, respectively) were measured. These measurements
were then used to calculate the neointimal (NI) area (area inside IEL – lumen area), the area
of the media (area inside EEL – area inside IEL) and NI area corrected for vessel size [(NI /
IEL) × 100].
Lesion composition was determined by staining sections at the point of maximum
neointimal lesion area. Collagen content was identified by staining with Picrosirius red.
Macrophage and smooth muscle content were assessed by immunohistochemistry, for which
sections were deparaffinised, blocked with normal goat serum, incubated with primary
antibodies followed by appropriate secondary antibody and Extravidin-Peroxidase LSAB
reagent, developed with DAB substrate and counterstained with haematoxylin. Primary
antibodies used were purified monoclonal anti-mouse Mac2 antibodies for macrophages
(1:6000; Cedarlane, UK) and monoclonal anti-mouse α-smooth muscle actin antibodies for
smooth muscle cells (1:400; Sigma-Aldrich, UK). Photomicrographs of stained sections
were acquired as described and quantification performed using a semi-automated colour
deconvolution process with Photoshop CS3 Extended software (Adobe Systems Inc., USA).
Statistics
Data are mean ± SEM, where n indicates the number of mice in each group. Statistical
analyses were performed using GraphPad prism (GraphPad Software Inc., California, USA).
The statistical tests used are indicated in the figure legends.
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RESULTS
Pharmacological glucocorticoids act locally to reduce neointimal lesions in C57Bl/6J mice,
mimicking the effect of systemically administered synthetic glucocorticoids
To confirm the utility of the model for testing corticosteroid effects, mice were treated
systemically with the potent GR agonist dexamethasone (1 mg/kg/day by daily subcutaneous
injection). Dexamethasone substantially reduced fibro-proliferative lesion area (Figure 1A),
but also delayed wound healing and prevented weight gain following surgery (Table 1) and
reduced the weights of glucocorticoid-responsive organs including the adrenal glands
(0.011±0.001% vs. 0.018±0.001% of body weight, p=0.001) and thymus (0.05±0.01% vs.
0.17±0.01% of body weight, p<0.0001).
To avoid these systemic effects, and to test the effects of a non-synthetic glucocorticoid,
cortisol was administered by implantation of a silastic pellet next to the injured artery.
Cortisol was selected over the endogenous murine glucocorticoid corticosterone to allow
assessment of systemic release; no cortisol was detected by radioimmunoassay in the
systemic circulation of these animals (data not shown), and there was no effect on body
weight (Table 1) or weights of the adrenal glands and thymus (not shown). However, local
cortisol release substantially reduced the area of the neointimal lesion following intra-
vascular injury, in comparison with vehicle-treated controls either in the contralateral leg or
in animals not treated with cortisol (Figure 1B).
Adrenalectomy does not affect neointimal proliferation in C57Bl/6J mice
To test whether endogenous corticosteroids provide a net tonic suppression of vascular
proliferation, mice were adrenalectomised or sham-operated. Successful surgery was
confirmed by measuring terminal plasma corticosterone levels (Sham 560±41nM vs.
Adrenlaectomy 56±5nM; p<0.001). Adrenalectomy had no effect on body weight (Table 1),
neointimal lesion area (Figure 2A), smooth muscle content (45.6±11.1% vs. 52.7±9.3%,
p=0.5) or macrophage content (11.5±3.4% vs. 14.4±3.0%, p=0.5) of neointimal lesions.
MR antagonism attenuates but GR antagonism increases neointimal proliferation in C57Bl/
6J mice
To test for independent and distinct effects of MR and GR on neointimal proliferation, we
used corticosteroid receptor antagonists. To avoid compensatory activation of the
hypothalamic-pituitary-adrenal axis that results from systemic GR antagonism, the GR
antagonist RU38486 was administered locally by silastic implant (12) adjacent to the injured
artery. Plasma corticosterone levels (Control 89.6±14.1 nmol/L vs. RU38486 54.3±18.8
nmol/L, p=0.16) and body weights (Table 1) were not altered. Neointimal lesion size was
increased by local RU38486 administration in comparison with control mice with bilateral
vehicle implants (Figure 2B). Contralateral lesions in mice with RU38486 pellets inserted
were intermediate in size (Figure 2B), suggesting a degree of systemic leak of RU38486
insufficient to raise plasma corticosterone.
Systemic administration of eplerenone (200 mg/kg/day) did not alter body weight (Table 1)
or tail cuff BP (115±3 mmHg vs. 116±2 mmHg, p=0.8), but substantially reduced
neointimal lesion size (Figure 2C).
Neither 11β-HSD1 nor 11β-HSD2 influence neointimal proliferation in C57Bl/6J mice
To test the influence of 11β-HSD1 and 11β-HSD2 on GR- and MR-mediated modulation of
neointimal proliferation, respectively, we studied mice deficient in either isozyme.
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11β-HSD2−/− mice were similar in weight to age matched C57Bl/6J mice (Table 1) but had
substantially higher systolic BP (Figure 3A) and, consistent with their chronic hypertension,
exhibited medial hypertrophy and outward vascular remodelling in uninjured vessels (Figure
3B). However, after femoral artery injury, there was no difference in size of neointimal
lesions between 11β-HSD2−/− and wild type mice (Figure 3C). To test whether the inhibition
of lesion size by MR antagonists was enhanced in 11β-HSD2−/− mice, which cannot
inactivate the potential MR ligand corticosterone, another group of 11β-HSD2−/− mice was
studied with and without eplerenone administration. Notably, eplerenone did not alter tail
cuff BP even in hypertensive 11β-HSD2−/− mice (Figure 4A). Body weights were similar in
all groups indicating no effect of eplerenone or 11β-HSD2 deletion. Eplerenone substantially
reduced neointimal proliferation in wild type as well as 11β-HSD2−/− mice (Figure 4B). This
effect of eplerenone on neointimal lesions was of no statistical difference between the two
groups, and there was no effect of 11β-HSD2 deficiency in the presence of eplerenone
(Figure 4B). Eplerenone reduced the macrophage content in both C57Bl/6J and 11β-
HSD2−/− mice but had no effect on collagen and smooth muscle cell content of neointimal
lesions (Figure 4C).
The effect of 11β-HSD1 deletion or pharmacological inhibition (with compound 544 17) on
neointimal proliferation was studied in C57Bl/6J mice. 11β-HSD1 inhibition had no effect
on body weight (Table 1) or systolic BP (110±2 mmHg vs. 112±2 mmHg, p=0.2). Deletion
of 11β-HSD1 had no effect on neointimal lesion size, an apparent reduction in lesion size
following administration of compound 544 was not statistically significant (Figure 5A).
However, there was no effect of 11β-HSD1 inhibition on composition of neointimal lesions
(Figure 5B).
11β-HSD1 inhibition reduces neointimal proliferation in atherosclerosis-prone Apo-E−/−
mice
The lack of a significant effect of 11β-HSD1 inhibition or deletion on neointimal lesion
development in C57Bl/6J mice contrasts with the atheroprotective effect of 11β-HSD1
inhibition observed in Apo-E−/− mice fed a high cholesterol Western diet (17). It is possible
that the pro-inflammatory effects of hyperlipidaemia and Western diet feeding increase
susceptibility to manipulations of 11β-HSD1 activity. Therefore, we administered compound
544 to Apo-E−/− mice on Western diet. 11β-HSD1 inhibition induced some weight loss
(Table 1), and tended to lower fasting plasma glucose and BP, but had no effect on plasma
lipid profile (Table 2). Following 11β-HSD1 inhibition, neointimal lesions were
significantly reduced in size (Figure 6A), with reduced macrophage content, elevated
collagen content and unchanged smooth muscle content (Figure 6B).
To determine whether the effects of compound 544 were due to selective 11β-HSD1
inhibition, post-angioplasty neointimal proliferation was also studied in Apo-E−/− and Apo-
E−/−, 11β-HSD1−/− (DKO) mice (n=8/group) fed on western diet for four weeks, starting
one week before wire-angioplasty. As with 11β-HSD1 inhibition, deletion of the enzyme on
an Apo-E−/− background lowered blood pressure and fasting glucose but had no effect on
plasma lipids (Table 2). Transgenic deletion of 11β-HSD1 in Apo-E−/− mice significantly
reduced lesion size compared with controls (Figure 6A). As with 11β-HSD1 inhibition, 11β-
HSD1 deletion had no effect on smooth muscle content (25±1% vs. 25±3%, p=1) but
reduced the macrophage (11±1% vs. 16±2%, p=0.02) and increased the collagen (40±3% vs.
30±3%, p=0.05) content of plaques compared with control mice.
DISCUSSION
Our data confirm that pharmacological administration of GR agonists reduces neointimal
proliferation following intra-vascular injury in mice, as previously demonstrated in dog, pig,
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rat, rabbit and human (1). This pharmacological effect appears to be mediated locally in the
vessel wall, since it is recapitulated by implantation of a slow-release device supplying
cortisol at the site of injury without increasing circulating glucocorticoid concentrations. GR
and MR (but not PR) are expressed in the media and neointima of mouse femoral arteries
and it is conceivable that glucocorticoid administration alters this micro-environment by
down-regulating GR. Moreover, our data show that MR antagonists reduce neointimal lesion
size in mice, as previously demonstrated in pigs (9, 10) and rabbits (8). In addition, we show
for the first time that GR antagonism exacerbates neointimal proliferation (although it
should be noted that RU38486 can also block progesterone receptors but we have found no
evidence that these receptors were present in the mouse femoral artery or its lesions).
Removing endogenous corticosteroid receptor ligands by adrenalectomy, however, had no
discernible effect on neointimal proliferation. These findings suggest that endogenous
corticosteroids sustain a balance between GR-dependent protective effects and MR-
dependent adverse effects.
Despite this evidence of tonic GR-mediated suppression of neointimal proliferation by
endogenous glucocorticoids, we found that preventing glucocorticoid regeneration by 11β-
HSD1 (which has been shown previously to influence GR-dependent vascular phenotypes
(11, 12), including atherogenesis (17)), had no significant effect on neointimal proliferation
or lesion content in C57Bl/6J mice. Indeed, inhibition or deletion of 11β-HSD1 was
paradoxically protective against neointimal proliferation in Apo-E−/− mice.
Endogenous glucocorticoids have well-established systemic effects on cardiovascular and
metabolic variables, many of which may influence neointimal proliferation. Manipulating
11β-HSD1 in liver and adipose tissue in mice has been shown to affect plasma glucose, lipid
profile and BP (20, 25-28), and pharmacological inhibition of 11β-HSD1 has similar
consequences (3). Our data in Apo-E−/− mice suggest that any influence of 11β-HSD1
inhibition on neointimal proliferation is likely to be dependent on systemic effects: although
11β-HSD1 inhibition or deficiency had no statistically significant influence either on
neointimal proliferation or on metabolic risk factors in C57Bl/6J mice on normal chow diet,
in Apo-E−/− mice challenged with a Western diet inhibition or deletion of 11β-HSD1 tended
to improve metabolic risk factors and reduced neointimal proliferation and intravascular
inflammation, as measured by macrophage content.
Regarding MR, the reduction in lesion size induced by eplerenone suggests a tonic
contribution of MR activation to neointimal proliferation. However, removing ligand by
adrenalectomy had no net effect. This could possibly be explained by the loss of opposing
GR and MR mediated actions, resulting in no overall effect. We also show that MR are not
‘protected’ from ligand activation by 11β-HSD2 in vessels in relation to vascular
remodelling as they are, for example, in the kidney in relation to BP control (5). Whether the
beneficial effect of MR antagonists on neointimal lesion formation is mediated by
alterations in systemic risk factors or by direct effects in the vessel wall remains a moot
point. The effects of eplerenone appear to be dissociated from any antihypertensive effect.
Thus, 11β-HSD2−/− mice had substantial systolic hypertension, as previously reported (19),
but this did not aggravate neointimal proliferation and was not measurably reduced by
eplerenone. Similar observations have been made in Apo-E−/−/11β-HSD2−/− double
knockout mice, in which eplerenone is atheroprotective without measurably lowering BP
(29). Eplerenone has also been shown to significantly reduce cerebral ischemia/neurological
deficit without any effect on blood pressure (30). Thus the results presented here suggest
that reduced neointimal proliferation in response to eplerenone treatment is not due to an
effect on systolic blood pressure. In other settings, MR activation is pro-inflammatory and
MR blockade reduces vascular inflammation (24, 31), observations which, together with the
reduced macrophage content observed in neointimal lesions following eplerenone treatment
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in the current studies, suggests an effect which might be mediated in non-resident
inflammatory cells.
11β-HSD1 inhibitors are being developed for use in patients with type 2 diabetes and have
beneficial effects on multiple metabolic cardiovascular risk factors (32-34). However, there
are increasing demands to document cardiovascular risk reduction for new oral
hypoglycaemic agents. There has been concern about pro-inflammatory effects of 11β-
HSD1 inhibition, resulting from reduced glucocorticoid concentrations in macrophages (13,
35). Certainly, loss of 11β-HSD1 is associated with prolonged inflammatory responses
following chemical peritonitis or serum arthritis (13, 14). However, effects of
glucocorticoids on inflammation are complex and context dependent, and loss of 11β-HSD1
has been associated with reduced indices of inflammation in adipose tissue (36). Arguably,
the most important conclusion from the current studies is that inhibition of 11β-HSD1 is
either neutral or protective, not only for atherogenesis (17) but also for vascular lesion
development following intravascular injury.
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Figure 1. Systemic or local glucocorticoid administration attenuates neointimal lesion formation
in C57Bl/6J mice
A) Systemic administration of a potent GR agonist, dexamethasone (DEX, 1 mg/kg/day by
daily subcutaneous injection), substantially reduced fibroproliferative lesion area. Data are
mean±SEM for n= 8/group and were analysed by Student’s un-paired t-test: *** indicates
p<0.001 vs. vehicle. Representative sections stained with United States Trichrome are
shown as insets (scale bar = 100 μm, arrows indicate internal and external elastic laminae).
B) Local administration of cortisol inhibited neointimal lesion formation. Extensive
neointimal lesions developed in vehicle-treated control arteries (either in the contralateral
control or in animals with bilateral vehicle pellets), but lesion formation was inhibited when
a 2mg cortisol pellet was placed next to the artery. Data are mean±SEM for n= 8-9/group
and were analysed by one-way ANOVA with Tukey’s post-hoc test: ** indicates p<0.01 vs.
vehicle; ns indicates non-significant. Representative sections stained with United States
Trichrome are shown as insets (scale bar = 100 μm, arrows indicate internal and external
elastic laminae).
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Figure 2. MR antagonism decreases, GR antagonism increases and adrenalectomy does not alter
neointimal lesion formation in C57Bl/6J mice
A) Adrenalectomy had no effect on neointimal lesion area in wire-injured femoral arteries in
C57Bl/6J mice. Data are mean±SEM for n= 7-8/group and were analysed by Student’s un-
paired t-test: ns indicates non-significant. Representative sections stained with United States
Trichrome are shown as insets (scale bar = 100 μm); arrows indicate internal and external
elastic laminae.
B) Locally administered GR antagonist, RU38486 (3.3mg), increased neointimal
proliferation in wire-injured arteries when compared with lesions in untreated mice;
contralateral control lesions were intermediate, suggesting some systemic effect of
RU38486. Data are mean±SEM for n= 8/group and were analysed by one-way ANOVA: ns
indicates non-significant, * indicates p<0.05. Representative sections stained with United
States Trichrome are shown as insets (scale bar = 100 μm); arrows indicate internal and
external elastic laminae.
C) Oral administration of an MR antagonist, eplerenone (200mg/Kg/day), reduced
neointimal proliferation after wire angioplasty in C57Bl/6J mice. Data are mean±SEM for
n= 6/group and were analysed by Student’s un-paired t-test: ** indicates p<0.01.
Representative sections stained with United States Trichrome are shown as insets (scale bar
= 100 μm); arrows indicate internal and external elastic laminae.
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Figure 3. Effects of 11β-HSD2 deficiency on blood pressure, vascular remodelling and neointimal
lesion formation
A) 11β-HSD2−/− mice had substantially higher systolic blood pressure, measured by tail cuff
plethysmography, than age-matched C57Bl/6J mice.
B) Uninjured femoral arteries showed medial hypertrophy and outward remodelling
resulting in a larger total vessel area.
C) Following intra-arterial injury neointimal lesion area was not different between groups.
Representative sections stained with United States Trichrome are shown as insets (scale bar
= 100 μm); arrows indicate internal and external elastic laminae.
Data are mean±SEM for n= 6/group and were analysed by unpaired Student’s t-tests. ns
indicates non-significant, * indicates p<0.05, ** indicates p<0.01.
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Figure 4. Effects of the MR antagonist eplerenone on neointimal lesions in C57Bl/6J mice and
11β-HSD2−/− mice
A) Eplerenone had no effect on systolic blood pressure in either normotensive C57Bl/6J or
hypertensive 11β-HSD2−/− mice (p=0.6).
B) Eplerenone reduced neointimal area in both C57Bl/6J and 11β-HSD2−/− mice.
C) Eplerenone reduced macrophage content of lesions (staining for Mac-2), but did not
affect smooth muscle (α-smooth muscle actin staining) or collagen (Picrosirius red) content.
Data are mean±SEM for n= 6/group and were analysed by two-way ANOVA and post hoc t
tests when appropriate. ns indicates non-significant, ** indicates p<0.01.
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Figure 5. Effects of 11β-HSD1 inhibition/deletion on neointimal lesion formation in C57Bl/6J
mice
A) In mice on a C57Bl/6J background, neointimal lesions were similar in 11β-HSD1−/− mice
and wild type controls, and were not significantly affected by compound 544.
Representative sections stained with United States Trichrome are shown as insets (scale bar
= 100 μm); arrows indicate internal and external elastic laminae.
B) 11β-HSD1 inhibition did not affect macrophage (staining for Mac-2), collagen
(Picrosirius red) or smooth muscle (α-smooth muscle actin staining) content of lesions.
Data are mean±SEM for n= 6/group and were analysed by un-paired Student’s t-tests. ns
indicates non-significant.
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Figure 6. Effects of 11β-HSD1 inhibition/deletion on neointimal lesion formation in Apo-E
knockout mice
A) In Apo-E−/− mice fed on Western diet, administration of the selective 11β-HSD1
inhibitor compound 544 reduced neointimal lesion size. Mice with transgenic deletion of
Apo-E and11β-HSD1 (double knockout, DKO) also had significantly lower neointimal
proliferation than Apo-E−/− mice. Representative sections stained with United States
Trichrome are shown as insets (scale bar = 100 μm); arrows indicate internal and external
elastic laminae.
B) Selective 11β-HSD1 inhibition also reduced macrophage content, elevated collagen
content and had no effect on smooth muscle content of lesions.
Data are mean±SEM for n= 6-8/group and were analysed by un-paired Student’s t-tests. ns
indicates non-significant, * indicates p<0.05.
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Table 1
Effects of corticosteroid manipulation on body weights
Intervention Time point*
Body Weight (g)
p
Controls Intervention
Systemic dexamethasone
Baseline 26.6±0.6 25.8±0.4 0.3
4-weeks 28.5±0.5 25.3±0.3 <0.0001
Local cortisol
Baseline 28.8±1.1 27.8±1.9 0.7
4-weeks 29.3±1.0 28.1±1.6 0.5
Adrenalectomy
Baseline 30.0±0.8 29.4±0.6 0.6
4-weeks 28.4±0.5 28.2±0.5 0.7
GR antagonism (RU38486)
Baseline 28.8±1.1 28.7±0.7 0.9
4-weeks 29.3±1.0 29.2±0.6 0.9
MR antagonism (eplerenone)
Baseline 29.3±0.7 28.5±0.5 0.4
4-weeks 30.9±1.0 29.0±0.7 0.2
11β-HSD2 deletion in C57Bl/6J
Baseline 29.3±0.7 28.7±0.4 0.5
4-weeks 29.3±1.0 28.1±0.6 0.3
11β-HSD1 deletion in C57Bl/6J
Baseline 29.5±0.7 30.0±0.4 0.5
4-weeks 30.0±0.5 30.7±0.8 0.5
11β-HSD1 inhibition in C56Bl/6J
Baseline 29.0±0.7 29.1±0.5 0.9
4-weeks 29.1±0.9 28.5±0.4 0.5
11β-HSD1 deletion in Apo-E−/−
Baseline 29.9±0.9 26.2±0.4 <0.01
4-week 32.8±0.4 28.6±0.5 <0.001
11β-HSD1 inhibition in Apo-E−/−
Baseline 30.2±0.5 30.1±0.5 0.9
4-weeks 30.4±0.7 28.6±0.5 0.05
*
Baseline weights were measured one week before angioplasty and terminal weights 3 weeks after angioplasty
GR, Glucocorticoid receptor; MR, Mineralocorticoid Receptor; 11β-HSD, 11beta-hydroxy steroid dehydrogenase; ApoE−/−, apolipoprotein E
knockout mice. Date represent Mean ± SEM, for n= 6-8 mice / group.
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Table 2
Effects of 11β-HSD1 inhibition/deletion on systemic cardiovascular risk factors in
Western diet-fed Apo-E−/− mice
Parameter*
11β-HSD1 inhibition 11β-HSD1 deletion
Vehicle Inhibitor p Apo-E−/− DKO p
Systolic BP (mmHg) 116±6 108±3 0.09 117±3 110±4 <0.01
Fasting plasma glucose (mg/dl) 338±27 258±30 0.07 272±33 181±20 0.03
Plasma cholesterol (mmol/L) 8.1±0.6 8.2±0.6 0.9 8.9±1.4 8.8±1.3 0.9
Plasma triglycerides (mmol/L) 1.8±0.1 1.7±0.2 0.9 1.7±0.1 1.6±0.1 0.3
*All measurements are at 4 week time point. BP, blood pressure; 11β-HSD, 11beta-hydroxy steroid dehydrogenase; Apo-E−/−, apolipoprotein E
knockout mice; DKO, Double (Apo-E & 11β-HSD-1) Knockout mice. Date represent Mean ± SEM, for n= 6-8 mice / group.
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